Trusted Resource for Clinical Trials, Protocols & Progress
Tracking investigational products helps prevent dosing errors, supports regulatory inspections, and provides a clear audit trail of drug movement and usage. Agencies such as the USFDA and EMA require comprehensive documentation of IP accountability at all trial stages.
Click to read the full article.
IP reconciliation involves comparing the quantity of investigational product received, dispensed, returned, and remaining at each site. The goal is to account for every unit of IP distributed during the trial.
Click to read the full article.
Controlled substances are drugs classified under national regulatory schedules due to their potential for abuse and dependence. In clinical research, opioids, stimulants, sedatives, cannabinoids, and some antidepressants often fall under this category.
Click to read the full article.
Stability monitoring involves assessing how the quality of an IP varies over time under the influence of environmental factors such as temperature, humidity, and light. These studies determine the product’s shelf life and establish the expiration or retest dates.
Click to read the full article.
Vendors and contract manufacturing organizations (CMOs) play a vital role in ensuring the quality, safety, and regulatory compliance of the investigational product. Failure in oversight can lead to protocol deviations, compliance issues, product recalls, and trial delays.
Click to read the full article.
Investigational product records provide traceability, accountability, and assurance of patient safety. Incomplete, inaccurate, or poorly maintained records can lead to regulatory findings, trial suspension, or rejection of data.
Click to read the full article.
The cold chain is a temperature-controlled supply chain required to maintain the integrity of investigational products from manufacturing to administration. It includes a network of storage facilities, refrigerated transport, insulated packaging, and real-time monitoring systems.
Click to read the full article.
Temperature excursions and improper handling by vendors can lead to compromised drug stability, protocol deviations, and failed audits. Regulatory agencies like USFDA and CDSCO expect sponsors to ensure that vendors follow GMP/GDP principles and have documented, validated procedures in place.
Click to read the full article.
A temperature excursion occurs when an investigational product is stored or transported at a temperature outside the established range defined by its stability data. Even short-term excursions can impact the quality, potency, or safety of the drug.
Click to read the full article.
Biologicals, including monoclonal antibodies and gene therapies, and vaccines are complex molecules susceptible to degradation. Exposure to inappropriate temperatures, moisture, or light can compromise their safety and efficacy. Regulatory bodies like USFDA and EMA mandate validated packaging that maintains required temperature ranges throughout the cold chain process.
Click to read the full article.
